Lorraine L. Lipscombe, MD, MSc
Lipscombe LL. Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes. Ann Intern Med. 2009;151:JC4–8. doi: 10.7326/0003-4819-151-8-200910200-02008
Download citation file:
Published: Ann Intern Med. 2009;151(8):JC4-8.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use